Fenretinide is under clinical development by SciTech Development and currently in Phase I for Sezary Syndrome. According to GlobalData, Phase I drugs for Sezary Syndrome have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Fenretinide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fenretinide overview
Fenretinide is under development for the treatment of small-cell lung cancer, t-cell non-Hodgkin's lymphomas (T-Cell NHL) including cutaneous t-cell lymphoma (CTCL) subtypes mycosis fungoides (MF) and sezary Syndrome (SS), non-cutaneous t-cell lymphoma (non-CTCL) subtypes angioimmunoblastic t-cell lymphoma (AITL), anaplastic large cell lymphoma and peripheral t-cell lymphoma (PTCL). It is developed as nanometer-sized liposomes using vehicle SDV, triglyceride-free drug formulation. The drug candidate is administered through the intravenous route and formulated as suspension. Fenretinide is a synthetic retinoid derivative related to vitamin A (retinol). It was also under development for follicular T-cell lymphoma.
It was also under development for the treatment of coronavirus disease (COVID-19) and follicular t-cell lymphoma (FTCL).
SciTech Development overview
SciTech Development Inc has developed a proprietary nanoparticle delivery platform to maximize the bioavailability of water-insoluble therapeutics, while improving safety profiles. The company is headquartered in Grosse Pointe Farms, Michigan, the US.
For a complete picture of Fenretinide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
